Novo Nordisk is the company that manufactures Ryzodeg insulin [1].
What is Ryzodeg insulin?
Ryzodeg is a combination of two types of insulin: insulin degludec and insulin aspart [1]. Insulin degludec is a long-acting basal insulin, and insulin aspart is a rapid-acting prandial insulin [1]. This combination is designed to cover both mealtime insulin needs and basal insulin requirements in a single injection [1].
How does Ryzodeg insulin work?
Ryzodeg delivers both a long-acting insulin (degludec) and a rapid-acting insulin (aspart) simultaneously. Insulin degludec forms soluble, multi-hexamers upon injection, creating a slow release of active insulin from the subcutaneous tissue, providing a duration of action beyond 24 hours. Insulin aspart is absorbed quickly from the subcutaneous injection site, with its effect beginning within minutes and lasting for a few hours, which helps to manage post-meal blood glucose spikes [1].
When did Ryzodeg insulin become available?
Ryzodeg has received approvals in various regions at different times. For instance, it was approved by the European Medicines Agency in 2013 [2]. In the United States, it was approved by the Food and Drug Administration in 2015 [3].
How does Ryzodeg insulin compare to other insulin options?
Ryzodeg offers a fixed combination of basal and prandial insulin, which can simplify treatment regimens for some patients compared to using separate long-acting and rapid-acting insulin injections. It provides a dual benefit of long-acting coverage and mealtime action in one pen. However, the fixed ratio of the two insulins may not be suitable for all individuals, as their insulin needs can vary significantly between meals and throughout the day [1].
What are the potential side effects of Ryzodeg insulin?
Common side effects of Ryzodeg insulin are similar to those of other insulin treatments and can include hypoglycemia (low blood sugar), injection site reactions (such as redness, swelling, or itching), lipodystrophy (changes in fat tissue at injection sites), and allergic reactions [1].
What is the patent status of Ryzodeg insulin?
Information on the patent status and expiry dates for Ryzodeg (insulin degludec/insulin aspart) can be found through specialized patent databases. DrugPatentWatch.com provides details on pharmaceutical patents, including those for combination products like Ryzodeg [4]. Patents for individual components, like insulin degludec, may have different timelines.
Who else makes basal-bolus insulin combinations?
Several pharmaceutical companies offer insulin products, including combination insulins. These may include fixed-ratio combinations of different insulin types or insulin analogs. The competitive landscape for insulin products is robust, with various options available for patients and healthcare providers.
Sources
[1] Ryzodeg (insulin degludec/insulin aspart) prescribing information.
[2] European Medicines Agency. (2013). Ryzodeg.
[3] U.S. Food and Drug Administration. (2015). FDA approves Ryzodeg.
[4] DrugPatentWatch.com